Member Info for oscar22

@Lambo,

Your recent assertions regarding ImmuPharma and the Lanstead agreement necessitate a clarification to prevent the dissemination of potentially misleading information within this investor community.

1. Biotechnological Sector Dynamics:

It's vital to remember that IMM's operations and dealings, particularly in a complex sector like biotech, aren't as simplistic as they may sometimes appear. Clinical trials, agreements, and partnerships take time to develop and implement. The sheer nature of the biotech sector is one of careful, meticulous planning and extensive regulatory oversight. Delays can be frustrating, but they're not necessarily indicative of any underlying issue; instead, they can often be a sign that the company is ensuring everything is in place for the best possible outcomes.

2. Factuality Over Speculation:

It's essential to distinguish between opinion and fact. While it's valid for each of us to have our interpretations of events, asserting an opinion as a factual claim without concrete evidence can be misleading to fellow investors. This is especially true when discussing potential share sales, as many factors come into play, and speculating without the full picture can lead to misunderstandings. I urge prudence in your assertions to avoid propagating inaccuracies.

3. Trust in IMM and Avion's Strategic Approach:

I hold unwavering confidence in ImmuPharma's strategy, which is not just based on their historical performance, but also fortified by the invaluable experience and support of our esteemed partner, Avion. Their combined expertise and collaborative synergy are pivotal in navigating the intricacies of the upcoming clinical trials. I anticipate an update from Immupharma soon, shedding light on the current developments.

In the interim, let's ensure that our discussions are grounded in facts and constructive dialogue, rather than inadvertently misleading or causing undue concern among fellow investors.

Finally, let's remember Warren Buffett's sage advice: "The stock market is a device for transferring money from the impatient to the patient." Let's remain positive and patient. True value often reveals itself with time.

The aforementioned views represent my analysis based on current data and are not to be construed as investment guidance.

What Happened?

ImmuPharma has extended the duration of certain "Warrants" they have in Incanthera plc by 12 months.

What are Warrants?

Warrants give the holder the right (but not the obligation) to buy shares at a specific price within a certain timeframe. In this case, ImmuPharma has the right to buy shares in Incanthera at a price of £0.095 per share.

Details of the Warrants:

Originally, these warrants were set to expire on 6 September 2023. This means ImmuPharma had until this date to decide whether they wanted to exercise their right to buy these shares at the mentioned price.

With this extension, ImmuPharma now has until 6 September 2024 to make this decision.

Current Position in Incanthera:

ImmuPharma already owns 9,904,319 shares in Incanthera, which is 12.7% of Incanthera's total shares.

Additionally, Tim McCarthy, who is the Chairman of both ImmuPharma and Incanthera, owns 5.05% of Incanthera’s shares.

What does this mean for us as long-term investors?

The ability to buy shares at a predetermined price gives ImmuPharma a potential advantage, especially if Incanthera’s share price rises significantly above £0.095 before 6 September 2024. If Incanthera does well, and its stock price goes up, ImmuPharma can exercise its warrants and get those shares at a discount, which could be financially beneficial.

On the flip side, if Incanthera's share price stays below £0.095, then the warrants might not be exercised as it wouldn't be financially advantageous.

This agreement shows ImmuPharma's long-term confidence in Incanthera since they wanted to extend their right to buy shares at this price.

Why Agree to This?

There can be many reasons. Strategically, it provides ImmuPharma with flexibility and an option to increase its stake in Incanthera if it sees value in the future. Financially, it can be an opportunity to invest at a favorable price. The fact that no additional consideration is being paid by ImmuPharma for this extension also suggests that it's a favorable move for the company.

Disclaimer: The above is my personal interpretation and analysis based on publicly available information. It does not constitute investment advice or any other kind of professional advice, and should not be used as a basis for making investment decisions.

Today's RNS solidifies the belief that 2023 will be a transformative year for the company. Central to this transformation is the addition of two industry stalwarts to the Board.

Dr. Laurence Reilly's Inclusion: A Game Changer:

Late-stage Clinical Program Expertise: Having managed late-stage clinical programs to their approval, Dr. Reilly comes with a proven track record. This expertise is indispensable, given ImmuPharma's emphasis on its P140 autoimmune platform and the clinical trials at hand.

Commercial & Business Development Acumen: Dr. Reilly's roles, particularly at Royalty Pharma and through his consulting practice at Acumen Life Science Investment Consulting, showcase his capabilities in strategic consulting, due diligence, and commercial development. Such experience will be crucial in ImmuPharma's interactions with potential licensing partners and ensuring favorable terms.

Past Achievements: His tenure as Chief Medical Officer for Cellectar Biosciences, an oncology biotech company, and roles at Avillion, Pfizer, and Lundbeck vouch for his comprehensive industry knowledge. His oversight of co-development programs with giants like Pfizer, Merck KGaA, and AstraZeneca speaks volumes about his capability to collaborate and forge beneficial partnerships.

Legal Insight: With a Masters Degree in Law, Dr. Reilly adds a unique dimension to the Board, ensuring that ImmuPharma remains compliant and takes informed legal decisions, especially in the complex world of biopharmaceuticals.

Dr. Sébastien Goudreau: An Insider's Insight:

Deep Company Knowledge: Being with ImmuPharma since 2014, Dr. Goudreau understands the intricacies of the company. His prior role as research director gives him an intimate knowledge of the company's R&D strategies and potential.

Crucial Role in P140 Platform: His contributions to the P140 autoimmune platform, especially the successful PK study in 2022, signifies his instrumental role in steering some of the company's most promising programs.

Leadership Capabilities: As the CEO of ImmuPharma Biotech since 2021, he's demonstrated leadership capabilities that will be invaluable on the Board. Moreover, his direct involvement in the development of the Company's anti-infective programmes underscores his versatility and strategic importance.

Academic Excellence: Holding a PhD in Chemistry and postdoctoral studies at the renowned ETH Zürich stands as a testament to his academic rigor and expertise in the field.

Strategic Future Path: With Dr. Reilly and Dr. Goudreau's combined expertise, ImmuPharma appears better equipped to navigate the rigorous process of late-stage clinical trials, commercial negotiations, and business expansions. Their collective experience promises a holistic approach, combining clinical insights, business acumen, and strategic leadership.

In essence, these Board additions signal not just growth but strategic evolution for ImmuPharma.

Disclaimer: The above is based on

@CauldStream7 - I agree with your take on the situation. From the recent interview with ImmuPharma's CEO, Tim McCarthy, it seems highly unlikely that Avion is planning to fully acquire ImmuPharma. McCarthy did mention the focus of their collaboration being centered on the U.S. market, which potentially opens up possibilities for global partnerships. This solid collaboration seems to minimise the chances of a full acquisition, allowing ImmuPharma to continue independently and keep working towards sustained growth. This outcome seems optimal, especially for us long-term shareholders who are looking for consistent and profitable growth.

As for the concern about a potential placement, it seems unwarranted at the current low price. As confirmed by McCarthy, the company is well-funded and in a robust financial position until 2024, which negates the immediate need for additional funding through a share placement. Furthermore, McCarthy's optimism about the latest phase 2.3 clinical trials, as well as potential up-front payments from agreements related to Lupuzor and CIDP rights, suggest a positive financial future for the company.

From the information provided in the CEO interview, it's evident that ImmuPharma is not a company on the brink of a takeover or in a dire financial situation that would necessitate a placing. So, any concerns or inaccuracies in that direction should probably be dismissed. It appears the company is geared up for very exciting developments in the near future, and it would be wise to watch those closely.

Again, these are my interpretations based on the information provided, and like all investment decisions, they should be considered with the understanding of the potential risks involved.

1. ANTICIPATED LAUNCH OF PHASE 2.3 CLINICAL TRIALS IN PARTNERSHIP WITH AVION PHARMACEUTICALS

ImmuPharma CEO, Tim McCarthy, announced with optimism that the company and its U.S. partners, Avion Pharmaceuticals, are prepared to launch the latest phase 2.3 clinical trials. The revised trial design is expected to offer efficiency and more extensive data. McCarthy expressed gratitude for Avion's steadfast support, underscoring that this collaboration currently focuses on the U.S. market, thus opening up opportunities for future global alliances. This collaboration may lessen the likelihood of a full acquisition by Avion, thereby reducing the chances for ImmuPharma to be taken over. This prospect of continued independence and the potential for sustained growth could result in positive and profitable outcomes for long-term shareholders.

2. FINANCIAL VIGOR AND SUSTAINABILITY

Demonstrating the company's resilience, McCarthy affirmed ImmuPharma's solid financial standing, with sufficient funding secured until 2024. This assurance portrays a lower risk of financial dilution and reduces the likelihood of capital placings at the company's current market valuation of £10.4 million.

3. ADVANCEMENTS IN CLINICAL TRIALS DESIGN

In a progressive stride, ImmuPharma has modified its Lupus treatment trial to a phase 2.3 design from a conventional Phase 3 trial. According to McCarthy, this novel approach is expected to enhance efficiency and yield a rich volume of data. The estimated cost of this innovative trial structure is approximately $25 million, which is included as part of the agreement with Avion.

4. SIGNIFICANT REVENUE POTENTIAL FROM LUPUS TREATMENT

An optimistic future projection was outlined by McCarthy stating that ImmuPharma, along with Avion, anticipate that the Lupus treatment could potentially amass over a billion dollars in annual revenue in the U.S. Furthermore, he highlighted that the company could receive in excess of $100 million per year in royalties, adding significantly to the bottom line.

5. PROGRESSIVE GLOBAL STRATEGY

Though Avion currently holds the rights for the U.S., ImmuPharma retains the global rights, hinting at the possibility of forging new partnerships. McCarthy shared that ongoing discussions with potential partners are taking place to expand the Lupus treatment worldwide. In addition to this, there is also a high level of interest in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment from several parties.

6. INDUSTRY ENDORSEMENT AND SHARED ENTHUSIASM

Both McCarthy and Avion CEO, Art Dees, exhibited mutual excitement about advancing the Lupus treatment and shared the vision of a significant breakthrough for ImmuPharma. Dees' personal investment in ImmuPharma, an act that demonstrates confidence and commitment, was positively noted by McCarthy.

https://youtu.be/dYOqKZM9f7M

Disclaimer: This post is a personal opinion, based on publicly available information and is not inte

7. OPTIMISM AROUND NEWS FLOW AND FUTURE DEVELOPMENTS

McCarthy revealed an eagerness to share regular updates about the company's progress, signifying a commitment to transparency and shareholder engagement. He also spoke of the potential for a wealth of exciting news to come, not only regarding the Lupus and CIDP treatments but also about potential commercial deals.

8. EMPHASIS ON PATIENT-CENTRIC APPROACH

The company's commitment to improving patient lives was evident in McCarthy's comments about the positive impacts of the Lupus drug on patients from the Phase 3 trial. This patient-centric approach reflects the core values of ImmuPharma and provides a firm basis for their ongoing research and development efforts.

9. VALIDATION OF IMMUPHARMA'S STRATEGIES

McCarthy asserted that the guidance they've received from the FDA is highly positive and reinforcing, offering further validity to ImmuPharma's strategic direction. He also drew parallels with the successful pathways of pharmaceutical giants GSK and AstraZeneca, who've faced similar challenges but ultimately achieved FDA approval for their drugs.

10. GROWTH AND EXPANSION ANTICIPATED

Alluding to the future, McCarthy revealed a positive outlook for the company's potential growth and expansion, both in terms of new markets and product lines. With the groundwork set for the U.S. market through the partnership with Avion, ImmuPharma has a clear path to extend its footprint globally. The company is also proactively exploring opportunities to increase its product portfolio beyond Lupus and CIDP treatments, eyeing other potential areas in auto-immune disorders and oncology.

11. VALUE FOR SHAREHOLDERS

Reiterating the company's dedication to its shareholders, McCarthy emphasised that the management team is keenly focused on driving value. The potential billion-dollar annual revenue from Lupus treatment and the prospective royalties could significantly boost the company's valuation and, in turn, benefit shareholders. Regular updates and a commitment to transparency were also highlighted as key components of shareholder value.

12. STRONG LEADERSHIP AND EXPERIENCED TEAM

McCarthy lauded the expertise and experience of both the ImmuPharma and Avion teams. He emphasised the importance of having skilled professionals leading the drug development processes, from the initial clinical trials to successful market launch. The collaborative efforts and mutual respect between the teams were praised as significant factors driving the company's success.

13. CONFIDENCE IN MEETING TARGETS AND MILESTONES

With the resources and partnerships in place, McCarthy expressed confidence in meeting the upcoming targets and milestones. While specific timelines were not discussed in detail, he ensured that the team is doing everything it can to progress the trials and commercialisation efforts as quickly and effectively as possible.

Disclaimer: This post is a personal opinion, based on publicl

Hi Dallo,

I wholeheartedly agree with your analysis and viewpoint. I also suspect the recent stock price fluctuations could be attributed to short-term investors reacting to the FDA Lupuzor trial outcome or just volatility caused by other factors. However, as you've rightly pointed out, our focus must be on the long-term potential of Lupuzor and the broader implications for ImmuPharma. In the world of biotech investment, patience is often key.

The unwavering support of Avion Pharmaceuticals and the dedication of the ImmuPharma team to optimise patient outcomes, coupled with a well-designed adaptive clinical trial, cannot be underestimated. Lupuzor™, with its novel subcutaneous delivery method, offers a promising solution to lupus patients that potentially outshines other available treatments.

The impending launch of the Phase 2/3 trial under FDA's guidance and with Avion's continued support, only bolsters our confidence in the future of this innovative therapy. It's the mark of a critical milestone that could transform lupus treatment and significantly benefit long-term stakeholders.

Additionally, the strategic aspects you've highlighted - deals on Lupuzor's Rest of the World rights (excluding US) and Global rights for CIPD, along with potential bids for ImmuPharma, present significant catalysts that could unlock great value. We must remember, the stock price today does not reflect the potential worth of tomorrow, especially when we are considering a game-changer like Lupuzor™.

Given the current landscape, your estimate of a nearly £30-£50m value seems reasonable, if not conservative, considering the potential Lupuzor™ and ImmuPharma holds. As biotech long-term investors, we understand that the market's short-term responses often do not reflect the longer-term potential of a promising drug candidate.

Indeed, the next few months are poised to be exciting for ImmuPharma and its investors. I echo your sentiment and look forward to witnessing how these developments will unfold.

Disclaimer: This post is a personal opinion, based on publicly available information and is not intended as financial or investment advice.

Following the recent RNS, we are on the threshold of a significant turning point as the Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) for patients with systemic lupus erythematosus (SLE/Lupus) is set to commence in the second half of 2023.

- Unwavering Support from Avion Pharmaceuticals

Avion Pharmaceuticals, a renowned name in the pharmaceutical industry, continues to be a stalwart supporter of this groundbreaking venture. According to the existing license agreement terms, Avion will provide unyielding backing for the new clinical trial design. This is a testament to the immense potential of Lupuzor™, enhancing our anticipation for the upcoming clinical trial.

Art Deas, CEO of Avion, encapsulated this sentiment, stating, "The FDA has provided us with comprehensive guidance to commence the Phase 2/3 adaptive clinical trial for P140 (Lupuzor™), and we look forward to continuing our close collaboration with ImmuPharma to deliver a successful result for Lupus patients."

- Subcutaneous Dosing: A Strategic Advantage

The evolved trial design, distinct from ImmuPharma's previous clinical trials, maintains subcutaneous dosing, now at much higher concentrations. This strategic choice comes with several potential benefits:

° Bioavailability: Subcutaneous administration often improves drug bioavailability compared to oral delivery, potentially enhancing Lupuzor™'s efficacy.

° Patient Compliance: Self-administration is generally possible with subcutaneous dosing, leading to increased patient comfort and adherence.

° Predictable and Prolonged Effects: This method provides a more predictable absorption rate and can have extended therapeutic impacts, improving the drug's performance.

This decision reflects the company's unwavering commitment to optimising patient outcomes and comfort, and showcases Lupuzor™'s therapeutic advantage over other available treatments.

- Commencing Phase 2/3: A Crucial Step Forward

The upcoming initiation of the Phase 2/3 adaptive clinical trial marks a pivotal advancement in Lupuzor™'s development journey. Under the guidance of the FDA and with Avion's continued support, ImmuPharma is set to embark on this critical phase of clinical research. A successful trial will move us one step closer to making a meaningful difference in the lives of lupus patients globally.

As Lupuzor™ advances in its clinical journey, we are potentially on the cusp of a transformative moment in lupus treatment. In the biotech landscape, it is critical to see past the veil of short-term market fluctuations. The real value lies in the long game, especially when a breakthrough therapy like Lupuzor™ is in play. This could unlock significant value, marking a paradigm shift for both patient care and long-term stakeholders.

Disclaimer: This note is based on my personal interpretation and analysis based on publicly available information. It does not constitute investment advice or any other kind of p

Lordloadsoflolly, your superficial approach to the complex domain of biotech investing becomes quite apparent with each comment you share. It seems you struggle to fully grasp the profound potential held by revolutionary entities such as ImmuPharma. It's unfortunate that this skewed perspective only serves to distort the dialogue. Surely, brevity has its place, but when it mirrors a deficiency of comprehension and foresight, it does a disservice to the conversation. Undoubtedly, laughter is a welcome relief, but in the realm of investing, it is in-depth understanding and detailed analysis that hold the key to success. I implore you to broaden your knowledge base of the sector before resorting to dismissive, surface-level remarks. As this is my final response to you, it is clear that we operate on vastly divergent plains, and my vision evidently extends far beyond yours.

In today's exhilarating announcement, ImmuPharma PLC, a distinguished name in the realm of drug discovery and development, has taken a giant leap in its ongoing journey of innovation. The promising progress in its late-stage clinical programme for Chronic Idiopathic Demyelinating Polyneuropathy (CIDP) further cements ImmuPharma's commitment to advancing healthcare, and presents an array of compelling reasons for continuing engagement with this dynamic company.

1. Expansion of the P140 Platform's Scope:

ImmuPharma's P140 peptide platform stands as a testament to its innovative spirit. Already lauded for its effectiveness in addressing Systemic Lupus Erythematosus (SLE), the recent positive feedback from the FDA has extended the platform's applicability to CIDP as well. This broadening of P140's therapeutic reach reinforces the company's ability to navigate new territories in autoimmune and inflammatory diseases.

2. Tapping into a High-Need Market:

ImmuPharma's foray into the CIDP market represents a well-calculated stride into a domain characterised by significant unmet medical needs. With global sales projected to reach an impressive US$2.7bn by 2029, the company's impending Phase 2/3 adaptive clinical trial for CIDP aligns ImmuPharma with a potential growth trajectory that is both meaningful and substantial.

3. Pursuit of Orphan Drug Status:

ImmuPharma's intention to apply for Orphan Drug status alongside the Investigational New Drug (IND) application is a clear signal of its long-term strategic planning. Attaining this status would afford the company seven years of market exclusivity following approval, a valuable opportunity to fully leverage the potential of the CIDP market.

4. Navigating the Regulatory Waters with Ease:

Today's positive guidance from the FDA instils confidence in ImmuPharma's regulatory acumen. It is indicative of a potential smooth sailing through future regulatory processes, which bodes well for the company's ability to expedite its clinical development plans.

5. Stability through a Dual-Therapeutic Approach:

ImmuPharma’s strategic concentration is not singular. The company maintains a strong commitment to its Lupus programme, with a Phase 2/3 clinical trial for Lupus patients also scheduled to commence in H2 2023. This concurrent advancement in two crucial therapeutic areas imbues the company, and those closely engaged with it, with a sense of stability often elusive in the biotechnology sector.

In sum, ImmuPharma's recent progress demonstrates its robust potential for growth and resilience. The company’s diverse therapeutic portfolio, underscored by positive regulatory feedback and a clear strategic vision, provides ample reasons for sustained engagement. ImmuPharma’s unfolding narrative promises to be a journey of relentless innovation and steadfast commitment to improving patient care.

Disclaimer: This is a personal perspective, not investment advice. Please consult a financial

ImmuPharma "looking forward" to upcoming FDA meetings:

https://www.proactiveinvestors.co.uk/companies/news/1013492/immupharma-looking-forward-to-upcoming-fda-meetings-1013492.html

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy spoke to Thomas Warner at Proactive's London studio, following what he calls a "very busy time" for the specialty biopharmaceutical company.

He discusses the latest developments and next steps for the P140 platform, highlighting the importance of two upcoming meetings with the US FDA.
GLA long-term investors!

As a long-term investor, I am sharing my perspective on ImmuPharma's today's RNS announcement and ongoing progress.

1. Proactive and timely FDA engagement with solid regulatory progress: ImmuPharma's ability to secure a Type-C meeting date with the FDA for Lupuzor™ in lupus on 7th June 2023 and a pre-IND meeting date for P140 in CIDP demonstrates the company's strategic approach to regulatory engagement. Active collaboration with regulatory bodies is crucial for efficient drug development, addressing potential concerns early on, minimizing delays, and reducing risks. Timely FDA engagement and effective navigation of the complex regulatory environment foster a faster drug development process and enhance investor confidence in the company's potential for success. The momentum building in ImmuPharma's P140 franchise signifies the company's forward progress and dedication to advancing its drug development programs. This proactive and strategic approach to regulatory engagement, combined with the company's ability to make solid regulatory progress, represents a strong argument in favor of ImmuPharma's innovative drug development programs and the company's future growth potential.

2. Strategic partnership with Avion Pharmaceuticals: ImmuPharma's collaboration with Avion Pharmaceuticals brings together the expertise of both organizations, maximizing resources and increasing the likelihood of successful clinical outcomes. ImmuPharma's CEO, Tim McCarthy, has demonstrated a strategic approach to drug development, and this partnership with Avion is a testament to the company's commitment to leveraging external expertise to develop innovative therapies.

3. Adaptive clinical trial design: The Phase 2/3 adaptive study design for Lupuzor™ is an innovative approach that showcases ImmuPharma's commitment to efficiency in its clinical development process. This design accelerates timelines, reduces costs, and allows for earlier trial termination if efficacy is demonstrated, increasing the likelihood of a successful outcome.

4. Robust pipeline with P140 platform: ImmuPharma's P140 platform has shown potential in both lupus and CIDP, highlighting the company's ability to diversify and expand its pipeline. The broad potential of P140 in treating various autoimmune and inflammatory conditions underscores ImmuPharma's strong value proposition.

5. Targeting unmet medical needs: Lupus and CIDP represent diseases with high unmet medical needs. ImmuPharma's focus on these areas positions the company to address significant market gaps and capture substantial market share.

6. Future growth potential: The unique mechanism of action of P140 has been linked to other diseases, suggesting that the platform could be expanded further to treat additional conditions. This potential for future growth offers long-term investment opportunities and value creation.

NOTE: This analysis is not investment advice but merely reflects my personal opinion based on the avail

ImmuPharma's stock value has experienced a significant increase of +1.42 (71.00%) in the past 5 days (as of 17 Apr, 16:35 BST). In my personal opinion, the recent RNS announcement presents a compelling case for investment, with numerous strong and positive arguments that are likely to appeal to top investors worldwide. Let's delve into the key reasons behind this upward trajectory:

1. Expanding Pipeline: ImmuPharma's P140 is moving into its second indication for CIDP patients, showcasing the company's ability to diversify and expand its pipeline. The potential to treat a range of indications with the P140 platform, such as autoimmune and inflammatory conditions like lupus and CIDP, highlights the broad potential of ImmuPharma's drug candidates.

2. Addressing Unmet Medical Needs: CIDP is a rare neurological disease with high unmet medical needs. There are limited treatment options for CIDP patients, and ImmuPharma's P140 offers a promising alternative with its unique mechanism of action. By focusing on this underserved patient population, ImmuPharma demonstrates its commitment to innovation and addressing critical healthcare needs.

3. Market Potential: The CIDP market is expected to reach global sales of US$2.7 billion by 2029, providing a lucrative opportunity for ImmuPharma if P140 proves to be successful. A first-in-class treatment for CIDP would give the company a significant competitive advantage and a substantial share of this growing market.

4. Regulatory Progress: ImmuPharma has received confirmation of a pre-IND meeting date with the FDA, marking a critical step in the drug development process. This progress showcases the company's ability to navigate the complex regulatory environment and move its drug candidates closer to commercialization.

5. Orphan Drug Status: If ImmuPharma receives Orphan Drug status for P140 following the pre-IND meeting, the company will benefit from 7 years of market exclusivity post-marketing approval. This exclusivity provides a competitive advantage and the potential for substantial financial returns during that period.

6. Management Expertise: The company's management team, led by CEO Tim McCarthy, has demonstrated a strategic approach to drug development, collaborating with contract research organizations and CIDP opinion leaders from Europe and the USA. This collaboration showcases the company's commitment to leveraging external expertise to develop innovative therapies.

7. Potential for Future Growth: The unique mechanism of action of P140 has been linked to other diseases, suggesting that the platform could be expanded further to treat conditions like asthma, irritable bowel disease, periodontitis, and gout. This potential for future growth offers long-term investment opportunities and value creation.

NOTE: The information provided in this analysis is based on my personal opinion and for informational purposes only and should not be construed as investment advice or a recommendatio

@ lordloadsoflolly: you we saying??? Ramper?

I stand by my previous post (below). Good luck to all long term investors!

P140 clinical programThu 15:52
The recent RNS from ImmuPharma has brought some truly exciting news regarding P140 clinical program for chronic idiopathic demyelinating polyneuropathy (CIDP). Immupharma has secured a pre-IND meeting date with the FDA for the Phase 2/3 adaptive study of P140 in CIDP, marking a game-changing milestone as it will be the first pivotal clinical study of P140 in patients with this rare neurological disease.

What's even more thrilling is that following the pre-IND meeting, Immupharma plans to submit an application for Orphan Drug status. If approved, Immupharma will enjoy 7 years of market exclusivity post-marketing approval, giving Immupharma a significant edge in the CIDP market. And here's the icing on the cake: the CIDP market is projected to reach a staggering US$2.7 billion in global sales by 2029, showcasing the immense potential of P140 in this space.

To shed some light on the difference between Lupuzor and P140: Lupuzor is a specific formulation of the P140 peptide that Immupharma has developed for treating systemic lupus erythematosus (SLE). On the other hand, P140 is a versatile platform with the potential to address various autoimmune and inflammatory conditions, including CIDP. Both Lupuzor and P140 share a groundbreaking mechanism of action that selectively corrects the biological mechanisms responsible for autoimmune and inflammatory conditions.

In a nutshell, the recent announcement by Immupharma regarding the P140 clinical program for CIDP is nothing short of exhilarating! With the potential revenue from the booming CIDP market and the pursuit of Orphan Drug status, the value of investments in Immupharma could soar to new heights. I look forward to hearing more updates on this promising development, as it could have a massive impact on the lives of CIDP patients and the growth of investments in this domain.

Disclaimer: This note is for informational purposes only and should not be construed as financial advice. Please consult a professional financial advisor before making any investment decisions.

The recent RNS from ImmuPharma has brought some truly exciting news regarding P140 clinical program for chronic idiopathic demyelinating polyneuropathy (CIDP). Immupharma has secured a pre-IND meeting date with the FDA for the Phase 2/3 adaptive study of P140 in CIDP, marking a game-changing milestone as it will be the first pivotal clinical study of P140 in patients with this rare neurological disease.

What's even more thrilling is that following the pre-IND meeting, Immupharma plans to submit an application for Orphan Drug status. If approved, Immupharma will enjoy 7 years of market exclusivity post-marketing approval, giving Immupharma a significant edge in the CIDP market. And here's the icing on the cake: the CIDP market is projected to reach a staggering US$2.7 billion in global sales by 2029, showcasing the immense potential of P140 in this space.

To shed some light on the difference between Lupuzor and P140: Lupuzor is a specific formulation of the P140 peptide that Immupharma has developed for treating systemic lupus erythematosus (SLE). On the other hand, P140 is a versatile platform with the potential to address various autoimmune and inflammatory conditions, including CIDP. Both Lupuzor and P140 share a groundbreaking mechanism of action that selectively corrects the biological mechanisms responsible for autoimmune and inflammatory conditions.

In a nutshell, the recent announcement by Immupharma regarding the P140 clinical program for CIDP is nothing short of exhilarating! With the potential revenue from the booming CIDP market and the pursuit of Orphan Drug status, the value of investments in Immupharma could soar to new heights. I look forward to hearing more updates on this promising development, as it could have a massive impact on the lives of CIDP patients and the growth of investments in this domain.

Disclaimer: This note is for informational purposes only and should not be construed as financial advice. Please consult a professional financial advisor before making any investment decisions.

Dear CauldStream7,

ImmuPharma has near-term revenue opportunities that can generate significant income for the company.

The recently announced distribution agreement with Avion Pharmaceuticals provides ImmuPharma with a unique opportunity to introduce several Avion products into the European market, including prescription prenatal supplements, low-dose birth control, menopause support, as well as support for patients with Parkinson's Disease, hypothyroidism, and prescription iron supplements designed for optimized absorption. With market research indicating that the prenatal supplements market in Europe is expected to reach €1.15 billion by 2028 and the low-dose birth control market in the US estimated to be worth $1.2 billion, this partnership offers ImmuPharma potential revenue streams from product sales, licensing fees, and royalties. Furthermore, the market for Parkinson's disease treatments is projected to reach $9.5 billion by 2027, making this distribution agreement with Avion a significant opportunity for ImmuPharma to generate top-line product sales revenue for the first time in the company's history. This partnership with Avion Pharmaceuticals not only shows their continued support for ImmuPharma's Lupuzor program but also demonstrates their belief in ImmuPharma's ability to successfully bring products to market. With the support of Avion, ImmuPharma can accelerate the introduction of its products into the European market and establish itself as a player in the global pharmaceutical industry.

Additionally, ImmuPharma is actively exploring opportunities for collaboration with larger pharma companies that will yield upfront payments and other financial benefits. As a testament to this, the company has already entered into a collaboration agreement with Orano Med for the development of ImmuPharma Peptide (IPP), which has the potential to yield significant revenue streams. The collaboration includes upfront payments, as well as potential milestone payments and royalties. With Orano Med's expertise in nuclear medicine and ImmuPharma's innovative technology platform, the collaboration has the potential to develop novel cancer treatments that could benefit patients worldwide. The IPP program targets cancer treatment and represents a novel approach to treating solid tumors. The potential financial benefits of the collaboration agreement with Orano Med are substantial and could provide ImmuPharma with a diversified revenue stream in the short term and beyond. This collaboration demonstrates ImmuPharma's ability to attract top-tier partners in the pharmaceutical industry and further validates the company's technology platform.

In conclusion, ImmuPharma's near-term revenue opportunities offer significant income generation for the company.

DISCLAIMER: This is not investment advice and you should do your own due diligence and consult with a financial advisor before making any investment decision.

Following my previous comment, it is important to note that Lupuzor™ has already received Fast Track designation from the FDA. This designation is granted to drugs that treat serious or life-threatening conditions and fill an unmet medical need. It is intended to accelerate the development and review of such drugs, which can provide several benefits to the trial timeline.

One of the benefits of the Fast Track designation is that it can lead to more frequent interactions with the FDA, which can help to streamline the development and approval process. Additionally, drugs with Fast Track designation are eligible for Accelerated Approval and priority review of the New Drug Application (NDA), which can further accelerate the regulatory approval process.

ImmuPharma's estimates suggest that the Phase 2/3 adaptive trial for Lupuzor™ will commence in H2 2023 following submission through the FDA/PDUFA process. The adaptive design of the trial, combined with Fast Track designation, offers several advantages over traditional trial designs, including greater flexibility, increased efficiency, and potentially faster regulatory approval.

Furthermore, Lupuzor™ has shown promising results in previous clinical trials, demonstrating the potential to effectively treat lupus with a good safety profile. As a first-in-class therapeutic peptide that targets a specific autoantigen involved in the pathogenesis of lupus, it offers a more targeted and effective treatment option for patients.

In addition, Lupuzor™ has demonstrated a favorable safety profile in clinical trials, with no significant adverse effects reported. This is a crucial advantage over other lupus treatments that can have significant side effects, making Lupuzor™ a more tolerable and potentially more widely used treatment option for patients.

Overall, the Phase 2/3 adaptive trial design for Lupuzor™, combined with Fast Track designation from the FDA, presents a promising opportunity for investors interested in the pharmaceutical industry. With positive feedback from the FDA and promising results in previous clinical trials, Lupuzor™ has the potential to be a highly effective and well-tolerated treatment for lupus, addressing a significant unmet medical need for patients.

DISCLAIMER: This is not investment advice and you should do your own due diligence and consult with a financial advisor before making any investment decision.

The Phase 2/3 adaptive trial for Lupuzor™ is a clinical trial that combines both Phase 2 and Phase 3 testing into a single study. This adaptive design allows for greater flexibility and efficiency in the clinical trial process, potentially leading to earlier results and regulatory approval.

In the Phase 2 part of the trial, researchers will explore a range of doses of Lupuzor™ to determine the most appropriate dose for Phase 3 testing. This dose-finding study will help identify the optimal dose of the drug that provides the most benefit with the fewest side effects.

Once the most effective dose of Lupuzor™ is identified, the study will seamlessly progress into the Phase 3 part of the trial, which will evaluate the safety and efficacy of the drug at the chosen dose. The use of an adaptive design in the Phase 2/3 trial is expected to significantly reduce the overall timelines for the program compared to traditional designs and other clinical trials for lupus treatments.

One of the major advantages of the Phase 2/3 adaptive trial design is that it eliminates the need for a separate Phase 2 trial, which can take a few years to complete. This can lead to much faster results and regulatory approval, potentially speeding up the drug development process.

Additionally, the use of an adaptive design allows for more flexibility in the trial design, as the study can be modified based on emerging data or changes in patient demographics. This can help to optimise the selection of the most appropriate dose and increase the likelihood of success in Phase 3.

The Lupuzor™ clinical program is subject to change based on various factors such as patient recruitment, regulatory processes, and trial execution. However, ImmuPharma's estimates suggest that the trial will commence in H2 2023 following submission through the FDA/PDUFA process.

It's important to note that Lupuzor™ has already received positive feedback from the FDA, including Fast Track designation and Orphan Drug designation, which are intended to accelerate the development and approval of drugs that treat serious or rare conditions.

Lupuzor™ has also shown promising results in previous clinical trials, demonstrating the potential to effectively treat lupus with a good safety profile. The drug has the advantage of being a first-in-class therapeutic peptide that targets a specific autoantigen involved in the pathogenesis of lupus, potentially offering a more targeted and effective treatment option for patients.

Moreover, Lupuzor™ has demonstrated a favorable safety profile in clinical trials, with no significant adverse effects reported. This is a crucial advantage over other lupus treatments that can have significant side effects, making Lupuzor™ a more tolerable and potentially more widely used treatment option for patients.

DISCLAIMER: This is not investment advice and you should do your own due diligence and consult with a financial advisor before making any investment decision

I noticed there has been some confusion and misinformation circulating about ImmuPharma and its lead product, Lupuzor™. As an investor myself, I believe it's essential to rely on accurate and official sources of information to make informed investment decisions.

Regarding the ongoing Lupuzor™ clinical trial, I'd like to clarify that the upcoming trial is an adaptive Phase 2/3 study that will explore a dose-range in the Phase 2 part of the study, followed by seamless progression into the Phase 3 part of the study at the chosen dose. This one-protocol pivotal study is expected to significantly reduce the overall timelines for the Lupuzor™ clinical program, and the company aims to commence the trial during H2 2023. This design incorporates guidance from the FDA, which advised exploration of higher dose levels than have been used in the clinical program to date. A clean safety profile has already been established at higher doses, and this design is expected to lead to accelerated approval by regulatory agencies.

It's also essential to note that the last read-out showed that Lupuzor™ failed to meet its endpoints in the previous Phase 3 trial. However, the FDA has highlighted the dosage as a potential problem, and the upcoming adaptive Phase 2/3 trial will address this issue by exploring higher dose levels. As a result, if the upcoming trial is positive, Lupuzor™ will be suitable not only for the subpopulation with biomarkers but also the wider population, resulting in a bigger market.

The accelerated timeline for Lupuzor™ is expected to provide investors with significant revenue growth potential. By 2025, the global market for lupus treatment is expected to reach $3.1 billion. As a potential game-changer in the lupus treatment market, Lupuzor™ has the potential to capture a significant portion of the market and generate substantial revenue for ImmuPharma. While it's impossible to provide any guidance on P3 readouts at this stage, I believe we could expect the Phase 2 part of the trial to complete in 2024, followed by the Phase 3 results late 2025, pending FDA approval.

DISCLAIMER: This is not investment advice and you should do your own due diligence and consult with a financial advisor before making any investment decisions as this comment is based in my personal interpretation and opinion.

As a loyal investor to Immupharma, I have not sold any shares since 2019, and the recent update on their Lupuzor has provided several compelling reasons why I continue to invest in this company:
-Adaptive Phase 2/3 Trial Design: ImmuPharma's adaptive Phase 2/3 trial design for Lupuzor™ in SLE patients with its partner Avion Pharmaceuticals is a one-protocol pivotal study, allowing exploration of a dose-range in the Phase 2 part of the study, followed by seamless progression into the Phase 3 part of the study at the chosen dose. This new study design incorporates guidance from the FDA, which advised exploration of higher dose levels than have been used in the clinical program to date. A clean safety profile has already been established at higher doses. This design is expected to lead to accelerated approval by regulatory agencies, and the company aims to commence the trial during H2 2023.
-Faster Timelines: The new study design is expected to significantly reduce the overall timelines for the Lupuzor™ clinical program. The company expects the new design to be less costly overall, which is important for investors looking for a high return on their investment. The program is targeted to commence in H2 2023 following submission through the FDA/PDUFA* process.
-Market Potential: The Lupus market is estimated to be worth over $2 billion globally, and there is currently no cure for this chronic autoimmune disease. ImmuPharma is also exploring additional indications for Lupuzor™, such as the treatment of dermatomyositis and polymyositis, which could expand the market potential even further. These additional indications could bring in even more revenue in the future.
Strong Partnership with Avion Pharmaceuticals: ImmuPharma has a strong partnership with Avion Pharmaceuticals, a U.S.-based company with expertise in commercializing drugs in the dermatology and rheumatology markets. Avion has confirmed its support for the Lupuzor™ clinical program in Lupus, and the two companies are working together to optimize the clinical program. This partnership provides valuable resources and expertise to help ensure the success of the clinical program. In addition, Immupharma has agreed to explore the opportunity of introducing certain Avion drugs into the European market, which would generate top-line product sales revenue for the first time in Immupharma's history and contribute net positive cash flow to the Company.
Potential for Product Sales Revenue: Immupharma has the potential to generate significant product sales revenue from Lupuzor™ if the drug is successfully approved by regulatory agencies. The drug has already shown positive results in Phase 2 clinical trials, with a significant reduction in disease activity in patients with Lupus. With additional indications being explored, the potential for sales revenue is even greater.
This is not investment advice and you should do your own due diligence and consult with a financial advisor before making any inv